Lung cancer is the second most common type of cancer, affecting millions of people all around the world. We are dedicated to developing targeted, innovative therapies that improve patients’ quality of life and increase survival rates.
Our commitment to fighting lung cancer
At Janssen, we are developing a pipeline of treatments to tackle the challenges of specific, advanced lung cancers.
We are committed to fighting lung cancer with precision medicines and treatments that give patients more time and healthcare professionals more options to treat the more advanced stages of this deadly disease.
Structure of Lung cancer
An overview of Exon 20 insertions
Janssen’s focus: Non-Small Cell Lung Cancer (NSCLC)
At Janssen, we’re concentrating on developing targeted therapies for patients whose treatment options are limited and who tend to have poor outcomes. Specifically, we are working on addressing the need for targeted therapies that address specific subtypes of lung cancer, particularly for people with non-small cell lung cancer (NSCLC), one of the world’s most common and deadly cancers.
Lung cancer is the second most common cancer and the leading cause of cancer death for men and women globally. NSCLC is the most common type of lung cancer, with approximately 1.8 million people worldwide diagnosed with NSCLC each year.,
The five-year NSCLC survival rate is 24% and targeted therapies can help people with NSCLC live longer, with a better quality of life. NSCLC can be driven by a range of different mutations, with different characteristics. The EGFR (epidermal growth factor receptor) gene is one of those affected by these mutations.
EGFR exon 20 insertion mutations are a specific subtype of EGFR mutation. These mutations an uncommon form of EGFR-mutated NSCLC, and are known to be associated with poor survival outcomes.
lung cancer in numbers
• NSCLC is the most common type of lung cancer, accounting for 84% of all lung cancer diagnoses.
• IIt is estimated that between 3.7% and 10% of EGFR-positive patients have insertion mutations within exon 20 of the EGFR gene. That represents approximately 60,000 new cases each year, worldwide.,, ,,,,,
• Currently, there are no targeted therapies approved specifically for NSCLC patients with lung cancer who have epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
• Typically, EGFR exon 20 insertion mutations are associated with poor survival rates. The estimated overall survival for these patients is 16 months.
• EGFR mutations, including exon 20 insertions, are particularly prevalent in women, non-smokers, those of Asian ethnicity and cancers with adenocarcinoma histology.
“Lung cancer is the biggest cause of cancer death in Europe and has one of the lowest five-year survival rates for cancer patients. At Janssen, we are committed to developing innovative targeted therapies that address the unmet needs for specific types of lung cancer, such as those with EGFR mutated non-small cell lung cancer.”
M.D., Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen EMEA
Johnson & Johnson is uniquely positioned as a company that spans the entire spectrum of human health: medical devices, pharmaceuticals, and consumer products. As the most broadly-based healthcare company in the world, we partner with external companies across all parts of our business.
One such partnership scheme is our Lung Cancer Initiative (LCI), which aims to improve outcomes in lung cancer for patients in Europe and beyond. By developing partnerships and innovation, we can address the current challenges that face lung cancer patients across the world.
The initiative is being expanded to the EMEA region, with the same goal of finding better ways to screen, prevent and intercept lung cancer. We’ll be providing further information on our progress in EMEA soon.